Xofluza-Wearables Feasibility-Study
Key facts
- Who runs it
- Children's Hospital of Philadelphia
- Where
- Philadelphia, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 498 people enrolled
- Started
- 14 Dec 2023
- Ended
- 30 Apr 2025
- Type of study
- Interventional, 4 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Baloxavir Marboxil
- Record updated
- 11 July 2025
Who can take part
- Age
- 2 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 31 criteriaShow less
Who can take part
- Population 1: Potential Baloxavir treatment group (CHOP transplant subjects 5 years \& up)
- Willing CHOP male or female kidney, heart, liver or lung single or multiple transplant recipients aged 5 years or older as per FDA guidelines
- Willing to regularly wear a smartwatch and take an at-home positive respiratory virus (RV) panel which will include a diagnoses of Influenza A or B
- Have an antigen positive diagnoses of Influenza A or B (a PCR-based positive clinical diagnoses of Influenza A or B may be requested in "alarm positive plus antigen positive but asymptomatic" cases)
- Can be included if their treating physician prescribe prophylactic treatment of Baloxavir if the subject has been exposed to Influenza
- If Baloxavir is prescribed the study subject should be treated within 48 hours of symptom onset (regardless of the alarming time); Population 2: Potential Baloxavir treatment group (CHOP waitlisted subjects 5 years \& up)
- Willing waitlisted CHOP kidney, heart, liver or lung single or multiple transplant recipients aged 5 years or older, which are anticipated to have a transplant in the next 12 months; Population 3: Potential Baloxavir treatment group (non-transplanted household members)
- Non-transplanted household member of a CHOP transplant recipient or waitlisted patient
- Be at least 5 years of age
- Willing to regularly wear a smartwatch and take an at-home positive respiratory virus (RV) panel for diagnoses of Influenza A or B
- Have a Antigen-based positive diagnoses of Influenza A or B; Population 4: Non-Baloxavir treatment subjects
- CHOP transplant recipients and all other non-transplanted household members who are 2-4 years of age
- Subjects 5 years and up who are Influenza positive but whom do not receive Baloxavir treatment
Who cannot take part
- Any allergy to Baloxavir (although they can remain in the study as an influenza case or control without Baloxavir treatment, or if they have been treated with a different medication for influenza) or a recommendation from the study physicians'/transplant pharmacist(s) not to take Baloxavir
- If the subject is taking a prohibited medication. These include Influenza antiviral drugs with the exception of oseltamivir and baloxavir (such as peramivir, laninamivir, zanamivir, rimantadine, umifenovir or amantadine)
- A household transplant recipient is not participating in the study
- A recommendation from the study physicians'/transplant pharmacist not to take Baloxavir
- If the subject is taking a prohibited medication. These include Influenza antiviral drugs with the exception of oseltamivir and baloxavir (such as peramivir, laninamivir, zanamivir, rimantadine, umifenovir or amantadine)
- If the subject is pregnant or breast feeding at the time of early infection alerting
- Any allergy to Baloxavir (although they will remain in the study as an influenza case/control without treatment)
- If the subject is younger than 5 years of age
- If the subject is younger than 5 years of age
- Population 1:
- Subjects weighing < 20 kg
- If the subject is unable or unwilling to consent
- If the subject requires mechanical ventilation at time of enrollment
- Unwilling or unable to comply with the study requirements; Population 2: All exclusion criteria listed for Population 1; Population 3:
- Subjects weighing < 20 kg
- If the subject is unable or unwilling to consent
- If the subject is pregnant at screening
- Unwilling or unable to comply with the study requirements
Where in United States
- Children's Hospital of PhiladelphiaPhiladelphia, United States
About the trial
What the trial wants to find out
The goal of this prospective, interventional, single-center study is to assess whether the early detection of Influenza with smart wearable device algorithms and alerting, rapid testing, and subsequent Baloxavir treatment demonstrate better post-infection outcomes versus publicly available- and Centers for Disease Control (CDC)-derived national statistics for equivalent household populations as well as pediatric kidney, heart, liver, lung transplant recipients and waitlisted patients.
The 4 groups in the trial
- Population 1: Transplant RecipientsTreatment being tested
Participants who are a CHOP kidney, heart, liver or lung single or multiple transplant recipients aged 5 years or older will receive a single dose of Baloxavir.
Treatment: Baloxavir Marboxil
- Population 2: Waitlisted Patients for TransplantTreatment being tested
Participants who are waitlisted CHOP kidney, heart, liver or lung single or multiple transplant recipients aged 5 years or older will receive a single dose of Baloxavir marboxil.
Treatment: Baloxavir Marboxil
- Population 3: Household Members (Non-Transplant)Treatment being tested
Non-Transplanted Household Members aged 5 years or older will receive a single dose of Baloxavir marboxil.
Treatment: Baloxavir Marboxil
- Population 4: Non-Baloxavir treatment subjectsNo study treatment, for comparison
CHOP transplant recipients and all other non-transplanted household members who are 2-4 years of age. Subjects 5 years and up who are Influenza positive but whom do not receive Baloxavir treatment
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Feasibility Study of Xofluza Treatment of Influenza in Pediatric Transplant Recipients, Waitlisted Subjects and Household Members After Early Infection Alerting Using Wearable Devices
- Record updated
- 11 July 2025